A Phase 4 interventional study of Denosumab and Zoledronic acid in Postmenopausal Osteoporosis, sponsored by 424 General Military Hospital. Completed at 2 sites in Greece. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-03-11.
Sponsored by 424 General Military Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal — none open to participants now, 1 under way, none of them phase 3. Zoledronic Acid · Osteoporosis, Postmenopausal.
Among the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal, this one is the 10th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 4, and was the 6th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →None of the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →
Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 50 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2015.
This study's enrollment of 57 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 195 across the 10 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 8 most frequent:
424 General Military Hospital is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
424 General Military Hospital has 4 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies testing Zoledronic Acid in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05655013Aarhus University HospitalTreatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. The investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion would prevent the anticipated bone loss.
Discontinuation of denosumab results in a rebound rise of bone turnover markers and gradual loss of the achieved bone mineral density gains. In contrast, bisphosphonates, such as zoledronic acid, remain within the skeleton acting for several months or even years after discontinuation while maintaining bone mineral density despite the cessation of treatment. In this study, the investigators aim to evaluate changes in bone mineral density of the lumbar spine and the femoral neck, as well as in bone turnover markers one year after treatment discontinuation both in denosumab-treated women and in denosumab-treated women who switched to zoledronic acid infusion one year before treatment discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year
Drug: Denosumab
Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year
Drug: Zoledronic acid
Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
Also known as: Prolia
Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
Also known as: Aclasta
bone mineral density of the lumbar spine
differences between the 2 arms in the changes of lumbar spine bone mineral density measured by dual-energy X-ray absorptiometry
Time frame: from 12 to 24 months
bone mineral density of the femoral neck
differences between the 2 arms in the changes of femoral neck bone mineral density measured by dual-energy X-ray absorptiometry
Time frame: from 12 to 24 months
C-terminal telopeptide of type I collagen
differences between the 2 arms in the changes of C-terminal telopeptide of type I collagen
Time frame: from 12 to 15, 18, 24 months
propeptide of procollagen type I
differences between the 2 arms in the changes of propeptide of procollagen type I
Time frame: from 12 to 15, 18, 24 months
bone mineral density of the lumbar spine
differences between the 2 arms in the changes of lumbar spine bone mineral density measured by dual-energy X-ray absorptiometry
Time frame: from baseline to 12 months
bone mineral density of the femoral neck
differences between the 2 arms in the changes of femoral neck bone mineral density measured by dual-energy X-ray absorptiometry
Time frame: from baseline to 12 months
Ran from Jul 2015 to primary completion in Nov 2018, 40 months.
Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 40 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zoledronic Acid
Osteoporosis, Postmenopausal →
424 General Military Hospital